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Rastaldo R, Cappello S, Folino A, Berta GN, Sprio AE, Losano G,
Samaja M, Pagliaro P. Apelin-13 limits infarct size and improves
cardiac postischemic mechanical recovery only if given after ischemia.
Am J Physiol Heart Circ Physiol 300: H2308–H2315, 2011. First
published March 4, 2011; doi:10.1152/ajpheart.01177.2010.—We stud-
ied whether apelin-13 is cardioprotective against ischemia/reperfusion
injury if given as either a pre- or postconditioning mimetic and
whether the improved postischemic mechanical recovery induced by
apelin-13 depends only on the reduced infarct size or also on a
recovery of function of the viable myocardium. We also studied
whether nitric oxide (NO) is involved in apelin-induced protection
and whether the reported ischemia-induced overexpression of the
apelin receptor (APJ) plays a role in cardioprotection. Langendorff-
perfused rat hearts underwent 30 min of global ischemia and 120 min
of reperfusion. Left ventricular pressure was recorded. Infarct size and
lactate dehydrogenase release were determined to evaluate the sever-
ity of myocardial injury. Apelin-13 was infused at 0.5 M concen-
tration for 20 min either before ischemia or in early reperfusion,
without and with NO synthase inhibition by NG-nitro-L-arginine
(L-NNA). In additional experiments, before ischemia also 1 M
apelin-13 was tested. APJ protein level was measured before and after
ischemia. Whereas before ischemia apelin-13 (0.5 and 1.0 M) was
ineffective, after ischemia it reduced infarct size from 54  2% to
26  4% of risk area (P  0.001) and limited the postischemic
myocardial contracture (P 0.001). L-NNA alone increased postisch-
emic myocardial contracture. This increase was attenuated by apelin-
13, which, however, was unable to reduce infarct size. Ischemia
increased APJ protein level after 15-min perfusion, i.e., after most of
reperfusion injury has occurred. Apelin-13 protects the heart only if
given after ischemia. In this protection NO plays an important role.
Apelin-13 efficiency as postconditioning mimetic cannot be explained
by the increased APJ level.
APJ receptor; ischemia/reperfusion; myocardial protection; precondi-
tioning
APELIN IS THE ENDOGENOUS LIGAND for the G protein-coupled APJ
receptor. Human, mouse, rat, and cow apelin genes encode a
77-amino acid preprotein with the active sequence in the
COOH-terminal region (19, 43). Various fragments of apelin
have been isolated and classified according to the number of
amino acids. Among fragments, apelin-13 and -36 are the most
frequently studied, and apelin-13 is considered the most active
of them (40). Apelin receptors APJ have been found to be
similar to angiotensin II receptor type 1 (25, 30, 43), but
angiotensin II does not bind to APJ receptors (14, 30).
Apelin mRNA is expressed in several organs and tissues. In
the cardiovascular system, apelin and APJ receptors occur in
vascular smooth muscle, endothelial cells, and cardiomyocytes
(21, 22). Apelin exerts a positive inotropic effect (2, 42) and a
nitric oxide (NO)-driven vasodilator activity (14, 15). It pro-
tects the heart against ischemia/reperfusion (I/R) injury both
in vitro and in vivo, but the underlying mechanism is still
controversial (20, 40). In particular, a role of NO in medi-
ating apelin-induced cardioprotection has not yet been de-
fined (40, 50).
Zeng et al. (50) observed antiapoptotic and antistunning
activities by apelin administered in the same heart before and
after global ischemia, a protocol that cannot clearly indicate the
exact timing required to produce the protective effect.
A remarkable protection against I/R injury can be induced
with either ischemic preconditioning (preC) or postcondition-
ing (postC). Whereas preC is obtained with one or more brief
(a few min) coronary occlusions performed 5–10 min before
the onset of ischemia, postC consists of very brief (a few
seconds) occlusions carried out after the end of ischemia (36).
Some substances, e.g., adenosine, bradykinin, opioids, silde-
nafil, and sphingosine, are reported to behave like effective
preC or postC mimetic (4, 9, 12, 24, 27, 38, 39, 45, 49).
Nevertheless, no investigation has hitherto been performed
with apelin given as a preC mimetic, i.e., administered before
but not during ischemia.
Most studies with apelin have addressed either the postisch-
emic mechanical recovery or the reduction of the infarct size
(IS). Thus it remains unclear whether the mechanical recovery
is attributable to the reduction of IS only and/or to a direct
effect of apelin on postischemic mechanical function of myo-
cardium. Finally, although it has been reported that ischemia
induces APJ receptor overexpression (50), to our knowledge
the relationship between APJ overexpression and the cardio-
protective effect of apelin has not yet been investigated. This
issue is pivotal because APJ overexpression induced by isch-
emia may be functional to assess the role of apelin as a postC
mimetic. Therefore, the aims of the present investigation are
1) to assess the cardioprotective effects of apelin as a preC or
postC mimetic, 2) to determine whether the improved post-
ischemic mechanical recovery induced by apelin is mainly
attributable to the reduced IS and stunning or to the apelin
inotropic effects, 3) to determine whether NO is involved in the
protective mechanism, and 4) to evaluate APJ protein amount
after ischemia.
To these aims, we designed experiments whereby apelin-13
was given either before ischemia (Ap-preC) or during early
reperfusion (Ap-postC).
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MATERIALS AND METHODS
Animals
Six-mo-old male Wistar rats (Harlan-Italy, S. Pietro al Natisone,
Italy) weighing 300–400 g were housed three per cage in a ventilated
cage rack system under standard conditions. The present investigation
conforms with the Guide for Care and Use of Laboratory Animals
published by the US National Institutes of Health [DHEW Publication
No. (NIH) 85-23, revised 1996, Office of Science and health Reports,
DRR/NIH, Bethesda, MD20205] and are in accordance with the
Italian ethical guidelines (DL. 116, 27 Jan, 1992). The purposes and
the protocols of our studies have been approved by the Ministero della
Salute, Rome, Italy and by the Ethical Committee of the University of
Turin.
Isolated Heart Preparation
Ten minutes after heparin injection, animals were anesthetized with
urethane (1 g/kg) intraperitoneally. The hearts were rapidly excised
and placed in ice-cold Krebs-Henseleit buffer (127 mM NaCl, 17.7
mM NaHCO3, 1.26 mM MgCl2, 5.1 mM KCl, 1.5 mM CaCl2, 11 mM
D-glucose, and 10 g/ml xylocaine). Then the hearts were suspended
to a Langendorff apparatus and retrogradely perfused via aorta at
constant flow with the above Krebs-Henseleit buffer in a nonrecircu-
lating way. The perfusate buffer was saturated with a 95% O2-5%
CO2 gas mixture and infused at 37°C as previously described (3, 35).
The constant coronary flow was adjusted with a constant-flow
perfusion pump (Watson-Marlow 505DU; Falmouth, Cornwall, UK)
to obtain a level of 9 ml per min per g corresponding to a perfusion
pressure of about 80 mmHg during the stabilization period. Thereaf-
ter, the pump maintained the same flow level throughout the experi-
ments. A small hole in the left ventricular wall allowed the drainage
of the thebesian flow. Coronary perfusion pressure (CPP) was mea-
sured throughout the experiments with an electronic pressure trans-
ducer (Monitoring kit mk5-02 DTNVF; Abbott, Milan, Italy) con-
nected to the perfusion line (3, 35).
Left ventricular pressure (LVP) was measured with a similar
pressure transducer connected via a catheter to a polyvinyl chloride
balloon placed in the left ventricle through the left atrium. The balloon
was filled with saline to achieve a left ventricular end diastolic
pressure (LVEDP) of about 5 mmHg. No further changes of ventric-
ular volume were made during the experiment (3, 35). CPP and LVP
were continuously recorded by a data acquisition system (Lab-View
software; National Instrument, Austin, TX).
To keep the heart rate constant throughout the experiments, the
hearts were electrically paced at 280 beat/min by a Grass S11
stimulator (Grass Instruments, Quincy, MA). Pacing was stopped at
the beginning of the ischemia and restarted after the third minute of
reperfusion (3, 35).
Chemicals for buffer solution were purchased from Sigma-Aldrich
(St. Louis, MO). All the reagents necessary to assess myocardial
infarction were purchased from Merck (Garcia, NJ).
Experimental Protocols
Studies on myocardial protection by apelin. The apelin-13 frag-
ment (American Peptide, Sunnyvale, CA) was chosen because it has
been reported to exhibit the most potent effect on myocardial protec-
tion (40). After 20 min of stabilization, each heart underwent I/R
consisting of 30 min of global ischemia followed by 2 h of reperfu-
sion. Global ischemia was obtained by arresting the perfusion pump.
During ischemia the hearts were maintained at 37°C by the surround-
ing medium.
To find out the minimum dose of apelin-13 capable to reduce
reperfusion injury, in pilot experiments (n  2 for each concentra-
tion), the peptide was infused during the first 20 min of reperfusion at
0.1, 0.2, 0.5, and 1.0 M concentrations. Because 0.1 and 0.2 M
were ineffective (see RESULTS), the bulk of this study was performed
at apelin concentrations of 0.5 and 1.0 M. Hearts were randomly
assigned to one of the following experimental protocols (Fig. 1):
Group 1 (control; n  8): these hearts underwent I/R without any
addition. Group 2 (Ap-pre-0.5; n  7): these hearts were perfused
before ischemia with 0.5 M apelin-13 for 20 min followed by 10 min
of washout to mimic ischemic preconditioning. At the end of washout,
I/R was performed. Group 3 (Ap-post-0.5; n  5): after ischemia,
these hearts were perfused with 0.5 M apelin-13 during the initial 20
min of reperfusion to mimic ischemic postconditioning. Group 4
[Ap-post-0.5  NG-nitro-L-arginine (L-NNA); n  6]: these hearts,
perfused with apelin-13 after ischemia as in group 3, were treated with
100 M of the NO synthase (NOS) inhibitor L-NNA 5 min before
ischemia and during the first 25 min of reperfusion bracketing the
20-min infusion of apelin. Group 5 (L-NNA; n  4): in these hearts
L-NNA was administrated as in group 4 but without apelin-13. Group
6 (Ap-pre-1; n 4): because 0.5 M apelin-13 was ineffective before
Fig. 1. Experimental protocol. The isolated Langendorff-perfused hearts after stabilization underwent 30 min of global ischemia followed by 120 min of
reperfusion. Apelin-13, infusion of apelin; wo, wash out; L-NNA, infusion of NG-nitro-L-arginine (100 M). Ap-pre-0.5 or Ap-pre-1, infusion of apelin-13 (0.5
or 1.0 M) for 20 min before ischemia. Ap-post-0.5, infusion of apelin-13 (0.5 M) during the initial 20 min of reperfusion. AP-post-0.5  L-NNA, infusion
of apelin-13 during the initial 20 min of reperfusion and infusion of L-NNA 5 min before ischemia and during the first 25 min of reperfusion. L-NNA, infusion
of nitric oxide synthase (NOS) inhibitor 5 min before ischemia and during the first 25 min of reperfusion.
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ischemia (see RESULTS), we wanted to see whether the highest con-
centration (1 M) reported to be effective in reperfusion (40) protects
myocardium if used as a preconditioning agent. Thus in these hearts
apelin-13 was given before ischemia as in group 2 but at 1 M
concentration.
Assessment of myocardial injury. IS was measured with the nitro-
blue-tetrazolium technique. In brief, at the end of the experiments,
each heart was rapidly removed from the perfusion apparatus, and the
left ventricle was cut in 1–2-mm-thick circumferential slices. Follow-
ing 20 min of incubation at 37°C in 0.1% solution of nitro-blue-
tetrazolium in phosphate buffer, stained viable tissue was carefully
separated from unstained necrotic tissue and then weighed by an
independent observer. Because ischemia was global, the total left
ventricle mass corresponded to the risk area. The necrotic mass was
expressed as a percentage of the total left ventricular mass (3, 35).
Because, in isolated rat hearts, IP and PostC are known to reduce
the release of lactate dehydrogenase (LDH) during reperfusion (47),
this enzyme was measured in the effluent during the 2 h of reperfusion
as previously described (3). Data are expressed as cumulative values
throughout the reperfusion period.
Cardiac function assessment. LVP was measured. Developed
(LVDevP) pressure was calculated as the difference between left
ventricular systolic pressure (LVSP) and LVEDP. Also the maximum
rates of positive and negative changes in LVP (dP/dt) were calcu-
lated. The changes in LVDevP and dP/dt during reperfusion were
expressed as percents of the baseline value. Both of them were taken
as indices of contractility, whereas LVEDP increase was taken as an
index of myocardial contracture. Comparisons of these contractile
variables were made throughout the entire time course of reperfusion.
Studies of ischemia-induced APJ protein expression. To test the
effect of ischemia on APJ receptor protein level, 15 hearts, which did
not receive apelin-13, underwent 30 min of global ischemia followed
by 0, 7, 15, 30, 120 min of reperfusion (n  3 for each conditions).
To detect APJ protein basal levels, in three hearts ischemia was not
induced and the perfusion lasted only 20 min. All the hearts were
snap-frozen, stored at 80°C, and used for APJ protein analyses as
follows: frozen samples (100 mg) were homogenized to a powder and
resuspended in RIPA buffer. A sample of total proteins (100 g) was
then separated on a 10% SDS-PAGE and electrotransferred to a
PVDF membrane (Macherey-Nagel, Düren, Germany). Western blot
analysis was performed with the antibody APLNR (H300) (Santa
Cruz Biotechnology, Heidelberg, Germany) at 1:200 dilution. Anti-
rabbit horseradish peroxidase-conjugate secondary antibody (1:2,000)
(Sigma-Aldrich) was used. Labeled bands were detected with a
chemiluminescence kit (BioVision, Mountain View, CA).
Image acquisition and quantification was made with a Kodak
Image Station 440CF (Kodak, Rochester, NY). Each experiment was
done in triplicate.
Statistical Analysis
Data are expressed as means  SE. One-way ANOVA and New-
man-Keuls multiple-comparison test (for post-ANOVA comparisons)
were used to evaluate the statistical significance of the differences of
the variables among groups and for the molecular analysis data. All
analyses were carried out with GraphPad Prism version 5.00 (Graph-
Pad Software, San Diego, CA), with P 0.05 as the significant cutoff.
RESULTS
Infarct Size
In control hearts, IS was 54  2% of the left ventricular
mass (Fig. 2A). Pilot experiments showed that 0.1 and 0.2 M
apelin-13 during reperfusion did not affect IS (49–54% and
51–57% of the left ventricle, respectively). By contrast, IS was
reduced to 18–30% and 25–33% when apelin-13 concentration
was 0.5 and 1 M, respectively. Therefore, the minimum
apelin-13 concentration required to reduce IS in reperfusion is
0.5 M.
IS was not significantly changed with respect to the control
when apelin-13 was given before ischemia (Ap-pre), either at
Fig. 2. Myocardial ischemia-reperfusion injury. A: infarct
size expressed as percent of the left ventricle (%LV), taken
as the risk area. B: cumulative release of lactic dehydro-
genase (LDH) during the 2 h of reperfusion, expressed as
units per gram of wet heart (U/g wet wt).
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0.5 M (45  4%) or at 1 M (44  6%). However, IS was
significantly (P  0.001) reduced to 26  4% when apelin-13
was infused after ischemia (Ap-post 0.5). Infarct size in Ap-
post-0.5 was also significantly lower than in both Ap-pre-0.5
and Ap-pre-1 (P  0.05).
In presence of L-NNA alone, IS was similar to the control
(66  5%; P  ns vs. control). However, the protective effect
of Ap-post-0.5 was abolished by this NOS inhibitor (64  5%;
P  ns vs. control).
LDH Release
In the control hearts the cumulative LDH release collected
during 2 h of reperfusion was 672  139 U·l1·g1 (Fig. 2B).
LDH release was not significantly different when apelin-13
was given before ischemia either at 0.5 (443  44 U·l1·g1)
or at 1 M concentration (416  74 U·l1·g1), but it de-
creased significantly (P  0.05) to 186  68 U·l1·g1 when
apelin-13 was given during reperfusion (Ap-post-0.5). In Ap-
post-0.5  L-NNA and L-NNA hearts, LDH release were not
significantly different (863  107 U·l1·g1 and 833  134
U·l1·g1, respectively) from the control group but were sig-
nificantly higher (P  0.01 and P  0.05, respectively) with
respect to Ap-post-0.5.
Cardiac Function
When given before ischemia at both 0.5 and 1 M concen-
trations, apelin-13 showed the well-known transient inotropic
effect (6), which lasted a few minutes only and was over before
the end of the infusion.
In the control group, global ischemia and the subsequent
reperfusion caused an increase in LVEDP that began before the
end of ischemia (Fig. 3A), continued during the early reperfu-
sion, and then slightly decreased throughout the experiment. At
constant volume of the intraventricular balloon, LVEDP in-
crease can be taken as an index of myocardial contracture.
Whereas at both concentrations Ap-pre did not prevent LVEDP
from increasing, Ap-post strongly attenuated such increase.
The effect of Ap-post-0.5 on LVEDP was blunted in Ap-
post-0.5  L-NNA, so that LVEDP was not different from the
data observed in the control (Fig. 3A). Interestingly, despite the
marked increase (P  0.001) of contracture brought about by
L-NNA alone, Ap-post-0.5 in the presence of L-NNA was still
able to reduce LVEDP.
LVSP during reperfusion was not different from the baseline
values in all groups with exception of L-NNA group (Fig. 3B).
In fact, with respect to the other groups, in L-NNA group LVSP
increased to a significantly (P  0.001) greater extent.
Fig. 3. Changes in left ventricular pressure during
the 30 min of ischemia and the 120 min of
reperfusion. A: changes in left ventricular end-
diastolic pressure (LVEDP). The increase in
LVEDP (contracture) begins before the end of
ischemia. B: changes in left ventricular systolic
pressure (LVSP). C: percent recovery of left ven-
tricular developed pressure (LVDevP), with re-
spect to the normalized baseline. Measurements
were made at times (in min) indicated on x-axis:
immediately before the start of ischemia (30),
at the end of ischemia (0), and during the 120-min
reperfusion period. *P  0.001 Ap-post-0.5 vs.
all groups; #P 0.001 Ap-post-0.5 L-NNA vs.
L-NNA; §P  0.001 L-NNA vs. all groups. Sig-
nificance is related to the entire time course of
reperfusion.
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In reperfusion, LVDevP recovered to about 80% of the
basal value in Ap-post-0.5 (Fig. 3C). The recovery was
significantly (P  0.001) greater not only with respect to the
control group but also with respect to both Ap-pre-0.5 and
Ap-pre-1, Ap-post-0.5  L-NNA and L-NNA groups, which
showed LVDevP values nonsignificantly different from the
control group (Fig. 3C).
Similarly to LVDevP, the rates of contraction (dP/dt)
and relaxation (dP/dt) during reperfusion were signifi-
cantly increased (P  0.001) in Ap-post-0.5 hearts with
respect to all the other groups (Fig. 4). Notably, when given
alone, L-NNA significantly (P  0.05) reduced dP/dt with
respect to the administration together with apelin-13 (Ap-
post-0.5  L-NNA).
APJ Receptor Level after I/R
Western blot analysis was performed to evaluate the APJ
protein level in cardiac tissue in response to ischemia/reperfu-
sion. Whereas at 0 and 7 min of reperfusion we did not observe
any alteration of APJ expression, a significant (P  0.05)
increase was observed only at 15 min of reperfusion (Fig. 5).
DISCUSSION
Here we show that apelin-13 has protective effects in post-
ischemic hearts only when given as a postC mimetic immedi-
ately after ischemia, whereas it is not effective as a preC
mimetic. As the protective effect of apelin becomes blunted
when NO release is inhibited, its action is in part a NO-
dependent mechanism. Furthermore, the Ap-post-induced im-
provement of postischemic mechanical recovery does not ap-
pear related to increased levels of APJ proteins.
In the isolated rat heart model, the effects of the various
experimental maneuvers are assessed independently of extrin-
sic neural and humoral factors. Furthermore, this model allows
performing global ischemia. Although regional I/R is the most
prevalent clinical setting of acute myocardial infarction (11),
global ischemia avoids the fact that little variations in IS may
be relevant in percent if they occur in the small risk area of a
regional ischemia. In addition, global ischemia excludes any
interference of the collateral circulation although this is pre-
dicted not to exceed 7% in the rat heart (13, 29).
It has been reported that, in regional ischemia experiments
(20), the reduction of IS was obtained with the administration
of a low concentration of apelin (10 nM) in the correspondence
of early reperfusion. By contrast, in global ischemia experi-
ments (40), a remarkable reduction of IS (43%) was obtained
only when apelin was given after ischemia at 1 M, whereas
10 and 100 nM were ineffective. Starting from these data, in
preliminary experiments we tested different concentrations of
apelin-13 in the range 0.1–1.0 M and found that 0.5 M
apelin-13 provides a protection similar to that elicited by
Fig. 4. Changes in dP/dt during the 30 min of ischemia and
the 120 min of reperfusion. A: percent recovery of dP/dt
with respect to normalized baseline. B: percent recovery of
dP/dt with respect to normalized baseline. Measurements
were made at times (in min) indicated on x-axis: immediately
before the start of ischemia (30), at the end of ischemia (0),
and during the 120-min reperfusion period. *P  0.001
Ap-post-0.5 vs. all groups; #P  0.05 Ap-post-0.5  L-NNA
vs. L-NNA. Significance is related to the entire time course of
reperfusion.
Fig. 5. Expression of APJ receptor before and after ischemia. A: bar plot of APJ
protein expression fold changes with respect to the basal level ( 1) at
different time points. B and C: corresponding spot intensity of APJ evaluated
with Western blot analysis. -Actin protein expression was used for normal-
ization. Vertical line indicates that the presented bands were not juxtaposed in
the original film. Measurements were made at times (in min) indicated on
x-axis: immediately before the start of ischemia (30), at the end of ischemia
(0), and during reperfusion (7, 15, 30, 120). *P  0.05; 15 vs. 30 min; all
other observations are not significantly different from 30 min.
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higher apelin-13 concentrations. Therefore, in mimicking post-
conditioning, apelin-13 was infused at 0.5 M concentration
during the first 20 min of reperfusion, thus including the period
during which most of the injury takes place (35, 45, 52).
A point to consider is the selectivity of apelin-13 at the
concentrations tested. Although apelin-13/APJ selectivity has
been demonstrated for nanomolar concentrations (18) and we
cannot exclude that at high concentration apelin-13 can bind to
different receptors, experiments on APJ knockout mice showed
that apelin effect was also abolished when the peptide was
administered at micromolar concentrations, without suggesting
any involvement of other receptors (10, 12).
Is Apelin a PreC or a PostC Mimetic?
As in previous studies apelin-13 infusion started before
ischemia and either continued during a regional ischemia (20)
or restarted after global ischemia (50); no data is available to
assess the cardiac protection exerted by apelin as a preC
mimetic (36). This study shows that 0.5 M apelin-13 protects
the rat heart only when infused during the first 20 min of
reperfusion but not when given before ischemia. Thus, whereas
several compounds mimic both preC and postC (12, 44, 48),
apelin-13 mimics postC only.
The reason whereby apelin protects the heart if given after,
but not before, ischemia is not clear. However, one can spec-
ulate that, because of the clear involvement of NO in the
protective effect observed with apelin-postC (see also below),
timing and kinetics of the apelin-induced release of NO plays
an important role. This opinion is consistent with the our
previous observation (35) that, despite the well-known protec-
tive effect of NO in both ischemic preC and postC as evidenced
by the Reperfusion Injury Salvage Kinases (RISK) cascade,
NO may sometimes fail in reducing IS if released by NO
donors, independently of their concentration.
Is the Postischemic Mechanical Recovery Due to IS
Limitation Only?
The long-lasting postischemic mechanical recovery in Ap-
post-0.5 experiments cannot be explained by the inotropic
effect of the peptide. In fact, this effect is short-lasting (6) as
also observed in both Ap-pre-0.5 and Ap-pre-1. Therefore the
apelin-induced protection can be ascribed either to limitation of
IS or to prevention of myocardial contracture. Here we show
that apelin-13, in addition to the reduction of IS, also attenuates
myocardial contracture and improves contractility during rep-
erfusion (for putative mechanism see below). Indeed the long-
lasting reduction of LVEDP corresponds to improved LVDevP.
Thus the reduction in contracture becomes a reliable index of
myocardial protection (8, 33) together with IS reduction. Be-
cause the contractile function recovery was faster and greater
than that induced in various protocols of ischemic preC or
postC (17, 32), this supports the importance of apelin-induced
myocardial protection. We argue, therefore, that both IS and
contracture reduction determine the apelin-13-induced increase
in LVDevP, as also underlined by increased dP/dt (Figs. 3
and 4). When apelin-13 was used as a preC mimetic, it was
ineffective at both 0.5 M and 1.0 M with regard not only to
IS but also to mechanical performance.
Is NO Involved in Ap-postC Protection?
Although controversial (20), the RISK pathway was sug-
gested to mediate IS limitation by apelin-13 and -36 (40).
However, whereas Simpkin et al. (40) found that the total and
the phosphorylated levels of endothelial NOS (eNOS) were
unaltered by apelin, Zeng et al. (50) reported an apelin-induced
increase of eNOS activity in neonatal cardiomyocytes after
hypoxia and reperfusion. As preC and postC protection criti-
cally involves e-NOS activation (12, 37), we studied whether
the blockade of NOS suppresses the protective effect of apelin
against I/R injury. The effects of NOS inhibition in various
models on IS (1, 3, 31) and postischemic mechanical recovery
(23) have already been studied. Because L-NNA infusion
impaired apelin-induced protection with regard to both IS and
mechanical recovery, this finding points at NO as a mediator of
the protective effects of apelin-13.
The LVEDP reduction and the increase in -dP/dt with apelin-13
as a postC mimetic is consistent with the apelin-induced increase
of the sarco/endoplasmic reticulum Ca2-ATPase (SERCA) ac-
tivity (46), which reduces calcium overload via NO-dependent
mechanisms. In fact, it has been reported that myocardial produc-
tion of NO by eNOS and/or neuronal NOS may stimulate the
activity of SERCA (7, 28, 51) by removing the inhibitory effect of
phospholamban via nitrosylation of its cysteine residues (7). The
role of NO on SERCA activity might explain the severe contrac-
ture attributable to L-NNA administration, when also the basal
release of NO is impaired if not prevented. Because apelin-13 as
a postC mimetic attenuates this contracture, the contribution of a
NOS-independent mechanism cannot be excluded although our
observations do not reveal any precise mechanism. Nevertheless,
partial dichotomy is reported between the effects on IS and
contractile function in the postischemic phase (5, 16, 26, 33).
Is APJ Expression Involved in Ape-postC Protection?
Because in rat hearts Zeng et al. (50) found a significant APJ
protein overexpression 30 min after the end of ischemia, we
investigated whether the protective activity driven by apelin as
a postC mimetic is associated with earlier increase in APJ
protein level. Our findings, however, show that APJ protein
level is increased only after 45 min from the beginning of the
ischemia, i.e., 15 min after the beginning of reperfusion. This
result is in contrast with the notion that most of the ischemic
injury takes place at the very beginning of reperfusion (34).
Thus the link between apelin-13-induced protection and in-
crease in APJ protein level is not a satisfactory mechanism to
explain the protection obtained when apelin-13 is given as a
postC mimetic. As a matter of fact, our finding is consistent
with those by Smith et al. (41), who report that apelin infusion
in the initial 2.5–10 min of reperfusion triggers cardioprotec-
tion despite the lack of time correspondence with the increased
amount of APJ receptor (Ref. 50 and present study). However,
we cannot exclude that the APJ intracellular trafficking in-
duced by ischemia involves delocalization of the APJ receptor
from intracellular vesicles to the plasma membrane of surviv-
ing cells, a phenomenon that cannot be clearly detected by
Western blot methods.
In conclusion, the cardioprotective effects of apelin mimic
ischemic postC, but not preC interventions; the improved
mechanical recovery induced by apelin is attributed, not only
to reduced IS, but also to reduced postischemic diastolic
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contracture. Whereas the infarct limiting effect seems to be
fully NO dependent, contracture limitation is only partially
suppressed by apelin in the presence of NOS-blockade. The
timing of the increase in APJ protein level after ischemia
cannot explain the protective effect of apelin as postC mimetic.
The endogenous origin of this effective compound as well as
the peculiarity of being a postC mimetic warrants further
investigation into the mode of action of apelin-13 within the
pool of treatments under study for postinfarction therapy.
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